LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)

Alex De Caluwé, Isabelle Desmoulins, K. Cao, Vincent Remouchamps, A. Baten, E. Longton, K. Peignaux-Casasnovas, Guilherme Nader Marta, Luca Arecco, Elisa Agostinetto, Paulus Kristanto, Xavier Catteau, Denis Larsimont, Roberto Salgado, Christos Sotiriou, Philip Poortmans, M. Piccart, Michail Ignatiadis, Emanuela Romano, Laurence Buisseret